Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 9/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759273 | 0.93 | ALOX5 (0.34) | HTR1AALOX5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12759284 | 0.90 | ALOX5 (0.32) | HTR1AALOX5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12759292 | 0.89 | MEN1 (0.34) | HTR1AALOX5PDE4APDE4BPDE4C | |
| SCHEMBL12759266 | 0.88 | MRGPRX4 (0.36) | MRGPRX4HTR1AALOX5CSF1RBCHE | |
| SCHEMBL10021312 | 0.86 | FPR2 (0.32) | HTR1A | |
| SCHEMBL13579230 | 0.83 | FPR2 (0.34) | HTR1A | |
| SCHEMBL10021505 | 0.82 | HTR1A (0.31) | HTR1A | |
| SCHEMBL12759256 | 0.81 | ALOX5 (0.43) | MRGPRX4HTR1AALOX5CSF1RBCHE | |
| SCHEMBL12759271 | 0.81 | ALOX5 (0.34) | HTR1AALOX5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16307048 | 0.80 | ALOX5 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272837-B1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272837-A1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, OCIAD1, CCDC22 | MRGPRX4 4738/4885HTR1A 2791/4885ALOX5 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.